Publications and Presentations


Clinical Application of Polysialylated Deoxyribonuclease and Erythropoietin

Recent Patents on Drug Delivery & Formulation 2018, 12, 212-222


Development, validation and application of a polysialylation-dependent FVIII activity assay to measure SHP656 (BAX 0826), a next generation extended half-life recombinant factor VIII product

Laboratory tests;
Date: 17.02.2017


Nonclinical Safety of SHP 826 (BAX 826), a Next Generation Extended Half-Life Recombinant Factor VIII Product

Blood 2016 128:4977


Development of BAX 826, a Polysialylated Full-Length rFVIII with Significantly Improved PK Properties

Blood 2015 126:3536


Pharmacokinetics of BAX 826, a Polysialylated Full-Length rFVIII, in Hemophilia a Mice, Rats, and Cynomolgus Monkeys

Blood 2015 126:1073


Future of coagulation factor replacement therapy



Chemical polysialylation: Design of conjugated human oxyntomodulin with prolonged anorexic effect in vivo

Biochimie, 95 (2):264-70, 2013.

Polysialylation: Next generation to PEGylation

Controlled Release Society Newsletter, USA, 21-23, 2010.

Development and testing of solid dose formulations containing polysialic acid and insulin conjugates: Next generation of long-acting insulin

Journal of Diabetes Science and Technology, 4:532:539, 2010.

Site-specific polysialylation of an anti-tumor single chain Fv fragment

Bioconjugate Chemistry, 20(5): 924-931, 2009.

Modulation of antibody pharmacokinetics by chemical polysialylation

Bioconjugate Chemistry, 19(3): 643-650, 2008.

Polysialic acids: A new generation of polymers for peptide and protein delivery

Controlled Release Society Newsletter, 22(3):14-16, 2005.

Polysialylation: The new way

European Biopharmaceutical Review, Winter, 94-101, 2005.

Improving the therapeutic efficacy of peptides and proteins: A role for polysialic acids

International Journal of Pharmaceutics, 300: 125-130, 2005.

Polysialylation: The natural way to improve the stability and pharmacokinetics of protein and peptide drugs

Drug Delivery Systems and Sciences, 4 (No 1): 3-9, 2004.

Improving the pharmacokinetics of protein and peptide drugs: Nature's way

The Drug Delivery Companies Report, pp. 44-47, Autumn/Winter 2003.

Polysialylated insulin: Synthesis, characterization and biological activity in vivo

Biochim. Biophys. Acta, 1622:42-49, 2003.

The effect of polysialylation on the immunogenicity and antigenicity of asparaginase: Implications in its pharmacokinetics

International Journal of Pharmaceutics, 217: 215-224, 2001.

Polysialic acids: Potential in improving the stability and pharmacokinetics of proteins and other therapeutics

CMLS Cellular and Molecular Life Sciences, 57: 1964-1969, 2000.

Polysialylated proteins: An approach to improving enzyme stability and half-life in the blood circulation

S.T.P. Pharma Sciences 9: 61-66, 1999.

Polysialylated asparaginase: Preparation, activity and pharmacokinetics

Biochim. Biophys. Acta, 1341: 26-34, 1997.

Synthesis, characterization and properties of polysialylated catalase

Biochim. Biophys. Acta, 1293: 92-96, 1996.

Polysialic acids: Potential in drug delivery

FEBS Letters, 315:271-276, 1993.


PolyXen™ Technology

PEGS 2018; May 1, 2018; Boston, MA


Efficacy of BAX 826, a Polysialylated Full-length rFVIII, in Mouse Models of Hemophilia A

WFH World Congress; July 24–28, 2016; Orlando, USA


Interaction of BAX 826 (PSAylated rFVIII) With VWF and LRP1 – An in vitro and in vivo Assessment

WFH World Congress; July 24–28, 2016; Orlando, USA


Utilising polysialylation technology to enhance delivery of peptide and protein therapeutics

4th Annual Drug Delivery and Formulation Meeting, February 18-20, 2013, Berlin (Germany)

Advances in polysialylation technology

2nd Drug Delivery Conference: Drug Delivery and Formulation: Novel Technologies, July 24-25, 2012, London (UK)

Polysialylation: Next generation to PEGylation

Knowledge Transfer Network's - Biopharmaceutical Formulation Group Meeting, 13th June, 2012, Oxford (UK)

Clinical Experience with Polysialic Acid Technology

EPIC meeting, , May 2012, London (UK)

Phase I/II clinical studies with polysialylated insulin (SuliXen®) and erythropoietin (ErepoXen®)

9th International Symposium on Polymer Therapeutics: From Lab to Clinic, 28th-30th May 2012, Valencia (Spain)

ErepoXen®: Design, preclinical and early clinical development

8th International Symposium on Polymer Therapeutics: From Lab to Clinic, Valencia, Spain, May 2010.

Polysialylated erythropoietin: Synthesis and biological activity of the next generation of natural erythropoiesis stimulating agent

36th Controlled Release Society meeting, Denmark, 18-22 July, 2009.